RMC No. 93-2024: Updates to VAT-Exempt Medicines Following FDA Letter on TRAIN and CREATE Acts

RMC No. 93-2024 publishes FDA-endorsed updates to the VAT-exempt list of medicines under TRAIN and CREATE Acts, including additions and deletions, effective upon FDA publication. Businesses and tax practitioners handling pharmaceuticals must review the updated VAT-exempt list as endorsed by the Food and Drug Administration (FDA) and published by the Bureau of Internal Revenue. This […]

RMC No. 36-2024: Clarifying MCIT Computation for 2023 with Rate Adjustments

RMC No. 36-2024 clarifies MCIT computation for 2023, reinstating a 2% rate from July 1, affecting all corporations and requiring immediate adjustments in tax reporting. Corporations must adjust their calculation of the Minimum Corporate Income Tax (MCIT) for the 2023 taxable year due to a change in rates effective July 1, 2023. Businesses that previously […]

RMC No. 21-2024: Clarification on VAT Registration for Petroleum Importers in Freeport Zones and Special Economic Zones

RMC No. 21-2024 clarifies that petroleum importers in freeport and special economic zones may remain VAT-registered to claim input VAT refunds on zero-rated exports. Businesses importing petroleum products into Philippine freeport zones or special economic zones face an immediate compliance update. Registered Export Enterprises (REEs) directly importing petroleum products with no other VAT-subject activities can […]

RMC No. 6-2024: Implementing CREATE Act Guidelines and Updated FIRB Forms for Cooperatives

RMC No. 6-2024 publishes JAO No. 001-2023 and FIRB Advisory 017-2023, updating guidelines and templates for cooperatives claiming tax incentives under the CREATE Act. Cooperatives and tax officials must now follow the newly published guidelines implementing Sections 305, 306, 307, and 308 of the National Internal Revenue Code as amended by Republic Act No. 11534, […]

RMC No. 71-2023: Streamlined Guidelines for VAT Credit and Refund Claims in the Philippines

RMC No. 71-2023 provides streamlined mandatory requirements for VAT credit and refund claims, effective July 1, 2023, impacting all VAT-registered taxpayers. Businesses and VAT-registered taxpayers must act now to comply with the revised guidelines for filing Value-Added Tax (VAT) credit and refund claims. Effective July 1, 2023, RMC No. 71-2023 sets out mandatory documentary requirements […]

RMC No. 156-2022: Updates to VAT-Exempt Medicines List for Common and Chronic Illnesses

RMC No. 156-2022 updates the VAT-exempt medicines list under the CREATE Act, covering chronic and life-threatening conditions. Businesses must adjust VAT calculations immediately. Businesses and healthcare providers must now adjust their VAT calculations immediately for certain medicines prescribed for hypertension, diabetes, high cholesterol, tuberculosis, mental illness, and cancer. The Food and Drug Administration’s latest update, […]

RMC No. 119-2022: VAT Exemption for Newly Endorsed COVID-19 Medicines

RMC No. 119-2022 adds Nirmatrelvir + Ritonavir 150 mg + 100 mg tablets for COVID-19 to the VAT-exempt list, effective from FDA publication, impacting healthcare providers and distributors. Businesses and healthcare providers must update their VAT-exempt inventory immediately: the Food and Drug Administration has added Nirmatrelvir + Ritonavir 150 mg + 100 mg film-coated tablets […]

RMC No. 113-2022: Updates to VAT-Exempt Medicines under the CREATE Act Affecting COVID-19 Treatments

RMC No. 113-2022 updates the VAT-exempt medicines list under the CREATE Act, correcting and deleting certain COVID-19 treatments, effective July 1, 2022. Businesses must adjust VAT filings accordingly. Businesses dealing with pharmaceutical sales must immediately review their VAT compliance for medicines prescribed for COVID-19. Recent updates endorsed by the Food and Drug Administration now correct […]

RMC No. 112-2022: FDA-Endorsed Updates to VAT-Exempt Medicines Affecting Tuberculosis Treatments

RMC No. 112-2022 updates the VAT-exempt medicines list under the CREATE Act, adding tuberculosis medicines and removing COVID-19 medicines, affecting tax compliance for healthcare providers. Businesses in the pharmaceutical and healthcare sectors must immediately update their records and compliance processes due to the newly endorsed changes to the VAT-exempt medicines list. Certain medicines prescribed for […]

RMC No. 57-2022: VAT Exemption Expanded to Include Hypertension, Diabetes, and COVID-19 Medicines

RMC No. 57-2022 updates the VAT-exempt list under the CREATE Act to include medicines for hypertension, diabetes, and COVID-19, requiring businesses to adjust invoicing and VAT reporting. Businesses and healthcare providers must immediately account for the updated VAT-exempt status of certain medicines for hypertension, diabetes, and COVID-19, effective from April 27, 2022. Failure to recognize […]